Description
Cetrorelix is a gonadotropin-releasing hormone (GnRH) analog that inhibits LHRH and GnRH. Cetrorelix exhibits anti-inflammatory activity and has been used clinically as a treatment for infertility due to its suppression of FSH and LH levels. In animal models of benign prostatic hyperplasia (BPH), cetrorelix decreases levels of inflammatory cytokines and growth factors, decreasing prostate size and weight. Additionally, cetrorelix decreases levels of Bax, caspase 3, and cytochrome c, inhibiting chemotherapy-induced mitochondria-dependent apoptosis in granulosa cells in vivo.
References
Rick FG, Schally AV, Block NL, et al. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate. 2011 May 15;71(7):736-47. PMID: 20945403.
Zhao XJ, Huang YH, Yu YC, et al. GnRH antagonist cetrorelix inhibits mitochondria-dependent apoptosis triggered by chemotherapy in granulosa cells of rats. Gynecol Oncol. 2010 Jul;118(1):69-75. PMID: 20417958.
Reissmann T, Felberbaum R, Diedrich K, et al. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod. 1995 Aug;10(8):1974-81. PMID: 8567825.
